Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

Nature

Volumn 436, Issue 7051, 2005, Pages 725-730

  Chen, Zhenbang ^a   Trotman, Lloyd C ^a   Shaffer, David ^a   Lin, Hui Kuan ^a   Dotan, Zohar A ^a   Niki, Masaru ^a   Koutcher, Jason A ^a   Scher, Howard I ^a   Ludwig, Thomas ^b   Gerald, William ^a   Cordon Cardo, Carlos ^a   Pandolfi, Pier Paolo ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION ANALYSIS; CELLS; MUTAGENESIS; NONINVASIVE MEDICAL PROCEDURES; REGULATORY COMPLIANCE; TUMORS;

CELLULAR SENESCENCE; MUTATED GENES; NEOPLASTIC TRANSFORMATION; ONCOGENIC PATHWAYS;

ONCOLOGY;

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; TRYPTOPHAN;

MEDICINE;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CYCLE; CONTROLLED STUDY; GENE; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; MALIGNANT TRANSFORMATION; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN STABILITY; TRP53 GENE; TUMOR SUPPRESSOR GENE;

ADP-RIBOSYLATION FACTORS; ANIMALS; CELL AGING; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; FEMALE; FIBROBLASTS; MALE; MICE; PHENOTYPE; PHOSPHORIC MONOESTER HYDROLASES; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 23244460597     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03918     Document Type: Article

References (30)

1. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307-315 (2004).
2. Serrano, M. & Blasco, M. A. Putting the stress on senescence. Curr. Opin. Cell Biol. 13, 748-753 (2001).
3. Campisi, J. Cellular senescence as a tumour-suppressor mechanism. Trends Cell Biol. 11, S27-S31 (2001).
4. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
5. Di Cristofano, A. & Pandolfi, P. P. The multiple roles of PTEN in tumour suppression. Cell 100, 387-390 (2000).
6. Stambolic, V. et al. Regulation of PTEN transcription by p53. Mol. Cell 8, 317-325 (2001).
7. Mayo, L. D. & Donner, D. B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl Acad. Sci. USA 98, 11598-11603 (2001).
8. Zhou, B. P. et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nature Cell Biol. 3, 973-982 (2001).
9. Freeman, D. J. et al. PTEN tumour suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3, 117-130 (2003).
10. Trotman, L. C. & Pandolfi, P. P. PTEN and p53: who will get the upper hand? Cancer Cell 3, 97-99 (2003).
11. Schmitt, C. A. et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109, 335-346 (2002).
12. Suzuki, H. et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204-209 (1998).
13. Feilotter, H. E., Nagai, M. A., Boag, A. H., Eng, C. & Mulligan, L. M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16, 1743-1748 (1998).
14. Muller, M., Rink, K., Krause, H. & Miller, K. PTEN/MMAC1 mutations in prostate cancer. Prostate Cancer Prostatic Dis. 3, S32 (2000).
15. Hermans, K. G. et al. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosom. Cancer 39, 171-184 (2004).
16. Qian, J. et al. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Mod. Pathol. 15, 35-44 (2002).
17. Navone, N. M. et al. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J. Urol. 161, 304-308 (1999).
18. KIP1 cooperate in prostate cancer tumour suppression in the mouse. Nature Genet. 27, 222-224 (2001).
19. Trotman, L. C. et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 1, 385-396 (2003).
20. Jonkers, J. & Berns, A. Conditional mouse models of sporadic cancer. Nature Rev. Cancer 2, 251-265 (2002).
21. Wu, X. et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 101, 61-69 (2001).
22. Dimri, G. P. et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 92, 9363-9367 (1995).
23. Weinberg, R. A. The cat and mouse games that genes, viruses, and cells play. Cell 88, 573-575 (1997).
24. Miyauchi, H. et al. Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J. 23, 212-220 (2004).
25. Stewart, S. L., King, J. B., Thompson, T. D., Friedman, C. & Wingo, P. A. Cancer mortality surveillance-United States, 1990-2000. MMWR Surveill. Summ. 53, 1-108 (2004).
26. Levi, F., Lucchini, F., Negri, E., Boyle, P. & La Vecchia, C. Leveling of prostate cancer mortality in Western Europe. Prostate 60, 46-52 (2004).
27. Abate-Shen, C. & Shen, M. M. Molecular genetics of prostate cancer. Genes Dev. 14, 2410-2434 (2000).
28. Bykov, V. J. et al. Restoration of the tumour suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282-288 (2002).
29. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
30. Maeda, T. et al. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433, 278-285 (2005).